Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Sep 10, 2018 (8 years ago)

Tri-Mix Papaverine/Phentolamine/Alprostadil 150 mg/5 mg/50 mcg a)…

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Tri-Mix Papaverine/Phentolamine/Alprostadil 150 mg/5 mg/50 mcg a) Injectable NDC 69699-1332-05 b) (LYO) Powder NDC 69699-1332-05, Pharm D Solutions, Houston, Texas

Affected NDC 69699-1332-05

Compare with the code on your package — it is the most precise check available.

Drug: Papaverine

Recalling firm
Pharm D Solutions, LLC
NDC code
69699-1332-05
Origin
TX, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0191-2019 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Papaverine recalls

See all
Class I · High risk

Papaverine HCl Injection

Presence of Particulate Matter: Product contaminated with particulate matter identified as glass and/or paraformaldehyde

Ongoing Particulate / foreign matter American Regent, Inc. NDC 0517-4002-01 D-0800-2026

Other recalls by Pharm D Solutions, LLC

All 2018 recalls